• No results found

[PDF] Top 20 Treatment of Haemophilia A by Replacement Therapy using Factor VIII Inhibitors

Has 10000 "Treatment of Haemophilia A by Replacement Therapy using Factor VIII Inhibitors" found on our website. Below are the top 20 most common "Treatment of Haemophilia A by Replacement Therapy using Factor VIII Inhibitors".

Treatment of Haemophilia A by Replacement Therapy using  Factor VIII Inhibitors

Treatment of Haemophilia A by Replacement Therapy using Factor VIII Inhibitors

... as inhibitors for example immunoglobulin G (IgG) (Scandella et ...of inhibitors developing in those chronic haemophilic patients which exposes about 10 to 20 days to FVIII ...The treatment of ... See full document

7

Complications of haemophilia therapy

Complications of haemophilia therapy

... Intravenous replacement of the missing clotting factor is the most logical and appropriate treatment o f ...Before replacement therapy was available, bleeding episodes were treated with ... See full document

201

Prevalence of factor VIII inhibitors in haemophilia a patients who received factor VIII therapy

Prevalence of factor VIII inhibitors in haemophilia a patients who received factor VIII therapy

... of Factor VIII in the age group between 10 -20 years of ...most inhibitors develop in children with severe haemophilia ,exposure to FVIII during the first 6 months of ...FVIII therapy ... See full document

120

Natural history and clinical characteristics of inhibitors in previously treated haemophilia A patients: A case series

Natural history and clinical characteristics of inhibitors in previously treated haemophilia A patients: A case series

... High titre inhibitors interfere with factor 89 Vlll replacement therapy, which often becomes completely ineffective, and are associated with 90 high morbidity and mortality.[1] The highe[r] ... See full document

37

Barriers and perceived limitations to early treatment of hemophilia

Barriers and perceived limitations to early treatment of hemophilia

... Early treatment of bleeds in hemophilia patients, both with and without inhibitors, has been shown to be of immense benefit in the overall clinical ...early therapy of bleeding episodes, especially ... See full document

8

Case Report Total femoral replacement for treatment of a massive femoral hemophilic pseudotumor: a case report and review of the literature

Case Report Total femoral replacement for treatment of a massive femoral hemophilic pseudotumor: a case report and review of the literature

... clotting factor VIII replacement therapy in the perioperative period, the patient had a radical resection of HP and reconstruction with a custom total femoral ...Various treatment ... See full document

6

Rituximab for Treatment of Hemophilia A with High-Responder Inhibitors

Rituximab for Treatment of Hemophilia A with High-Responder Inhibitors

... to factor VIII of at least 5 BU/mL, inhibitor level greater than or equal to 5 BU/mL about 5 to 14 days after initial factor VIII exposure during screening and age over 5 ...cytotoxic ... See full document

8

Case Report Cementless total hip arthroplasty in patient with severe haemophilia A: a case report and literature review

Case Report Cementless total hip arthroplasty in patient with severe haemophilia A: a case report and literature review

... of Haemophilia (WFH) guide- line [19], replacement treatment was adminis- tered by bolus of factor VIII concentrates to achieve trough levels of 80% in the first 72 h postoperatively ... See full document

5

Generic and disease-specific quality of life among youth and young men with Hemophilia in Canada

Generic and disease-specific quality of life among youth and young men with Hemophilia in Canada

... coagulation factor VIII (FVIII) and lifelong bleeding manifestations, particularly repeated hemarthroses leading to permanent joint ...intensive factor replacement therapy is ... See full document

9

Modelling gene therapy for haemophilia

Modelling gene therapy for haemophilia

... gene therapy offers the potential o f a life-long cure for even severe haemophiliacs (see review, Brownlee, ...clotting factor gene into a somatic cell of a haemophiliac, the patient would be able to ... See full document

269

Neutralizing antiidiotypic antibodies to factor VIII inhibitors after desensitization in patients with hemophilia A

Neutralizing antiidiotypic antibodies to factor VIII inhibitors after desensitization in patients with hemophilia A

... els. Using a competition assay with mAbs, we further show that the specificity of human antibodies did not vary signifi- cantly during ...the treatment elicited antiidiotypic antibodies, which neutralized ... See full document

8

Challenges and successes in the treatment of hemophilia: the story of a patient with severe hemophilia A and high-titer inhibitors

Challenges and successes in the treatment of hemophilia: the story of a patient with severe hemophilia A and high-titer inhibitors

... of treatment and management have been costly and time-consuming, and have placed a considerable burden on patients’ physical and psychological ...on-demand therapy and prophylactic treatment ... See full document

7

Budget impact analysis of the use of extended half life recombinant factor VIII (efmoroctocog alfa) for the treatment of congenital haemophilia a: the Italian National Health System perspective

Budget impact analysis of the use of extended half life recombinant factor VIII (efmoroctocog alfa) for the treatment of congenital haemophilia a: the Italian National Health System perspective

... switching treatment regimen from on-demand to prophylaxis treatment for patients treated with plasma-derived therapy and conventional recombinant FVIII; a 5% switch rate was assumed based on the ... See full document

10

Human von Willebrand factor/factor VIII concentrates in the management of pediatric patients with von Willebrand disease/hemophilia A

Human von Willebrand factor/factor VIII concentrates in the management of pediatric patients with von Willebrand disease/hemophilia A

... the treatment of acute spontaneous or traumatic bleeding ...during treatment have never been reported in pediatric patients, and DDAVP is best avoided in adults with overt cardiovascular ...contraindicated, ... See full document

9

Many factor VIII products available in the treatment of hemophilia A: an embarrassment of riches?

Many factor VIII products available in the treatment of hemophilia A: an embarrassment of riches?

... of factor VIII (FVIII) with an incidence of ~1 in 5000 male ...births. Replacement of FVIII is nec- essary to prevent and treat bleeding ...FVIII treatment options is harder than ... See full document

7

The use of PEGylated liposomes in the development of drug delivery applications for the treatment of hemophilia

The use of PEGylated liposomes in the development of drug delivery applications for the treatment of hemophilia

... coagulation factor VIII (FVIII). Hemophilia A is treated with replacement therapy, but frequent injections of the missing FVIII often lead to the formation of inhibitory ...of ... See full document

11

Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving Emicizumab. Interim guidance from UKHCDO Inhibitor Working Party and Executive Committee

Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving Emicizumab. Interim guidance from UKHCDO Inhibitor Working Party and Executive Committee

... Treatment with additional haemostatic therapy should only be started if a bleed has definitely occurred. In patients receiving Emicizumab minor bleeds may resolve without additional haemostatic ... See full document

6

Acquired factor VIII inhibitor and lupus anticoagulant presenting with prolonged aPTT: a case report

Acquired factor VIII inhibitor and lupus anticoagulant presenting with prolonged aPTT: a case report

... of factor VIII inactivated by the patient’s plasma incubated with normal plasma under specific ...of factor VIII in a 1:1 mixture of the patient’s plasma and normal plasma (after a 2-h ... See full document

6

Effective prophylaxis with rFVIIa in young haemophiliacs with inhibitors using a schedule similar to FVIII prophylaxis in non inhibitor patients

Effective prophylaxis with rFVIIa in young haemophiliacs with inhibitors using a schedule similar to FVIII prophylaxis in non inhibitor patients

... with inhibitors can have dra- matically variable patterns of bleeding from unknown causes, this is the first complete report on early prophy- laxis with rFVIIa in high-response inhibitor haemophili- ... See full document

7

Continuous infusion of recombinant activated factor VII: a review of data in congenital hemophilia with inhibitors and congenital factor VII deficiency

Continuous infusion of recombinant activated factor VII: a review of data in congenital hemophilia with inhibitors and congenital factor VII deficiency

... safety, efficacy, and dosing data regarding CI of rFVIIa in patients with CHwI or C7D, and to compare CI outcomes to those of BIs, when available. Overall, we identified a total of 241 patients who experienced 453 ... See full document

13

Show all 10000 documents...